Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 + Toripalimab + Chemotherapy vs Sintilimab + Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma
NCT07584135Phase 3Recruiting
- Sponsor
- Junyan Hongshi Biosciences
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of JS107 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Junyan Hongshi Biosciences. Primary endpoints: Progression-Free Survival by BICR up to 2 years and Overall Survival up to 5 years. Started May 2026; status: recruiting.
02
Drugs
JS107
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07584135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584135.